Every Cure and OpenEvidence launch AI drug-repurposing partnership
Every Cure and OpenEvidence will pair AI drug-repurposing hypotheses with rare-disease physicians, clinical-trial referrals and point-of-care evidence distribution.
By Amara Osei
3 min read

What's News
- Every Cure and OpenEvidence announced the partnership on November 16, 2026.
- Every Cure targets roughly 18,000 recognized diseases lacking commercial incentives; only about 4,000 have approved treatments.
- More than 300 million people globally have a disease with no FDA-approved treatment, Every Cure estimates.
- OpenEvidence works with the National Organization for Rare Disorders on more than 3,000 expert-reviewed rare-disease summaries.
- David Fajgenbaum has been in remission for more than 11 years and has advanced 14 additional repurposed drugs, Every Cure says.
By Amara Osei
Every Cure and OpenEvidence announced a November 16, 2026 partnership to advance drug repurposing for the roughly 18,000 recognized diseases that Every Cure says lack commercial incentives for new treatments.
Every Cure and OpenEvidence said the partnership links AI-supported drug evaluation with specialist input, clinical-trial recruitment and evidence distribution to physicians. Every Cure estimates that only about 4,000 of the recognized diseases have approved treatments.
Every Cure also estimates that more than 300 million people globally have a disease with no FDA-approved treatment. Every Cure said those figures frame the alliance’s target: promising uses for approved drugs, including generics, that a nonprofit can pursue without a conventional commercial return.
Every Cure said repurposing builds on an existing drug’s safety data and manufacturing capacity rather than starting with a new compound. It contrasted that foundation with new-drug development, which can require billions of dollars and more than 10 years. Every Cure cautioned that this rationale does not establish that any particular candidate will work in a new disease.
How will AI and specialists shape the research?
Every Cure applies data science and AI to evaluate approved drugs against diseases systematically, the company said. OpenEvidence said it will contribute proprietary models and biomedical sources and data, including content from its strategic partnership with Nature journals, to help assess repurposing hypotheses.
OpenEvidence will match individual programs with physicians who have cared for patients with the relevant disease, the company said. For many rare and underserved diseases, only a small number of such physicians exist, making that access central to the collaboration, according to the announcement.
Matt Goddeeris, Every Cure’s chief scientific officer, said: “OpenEvidence can help us reach the physicians who care for these patients.” He said physicians’ firsthand experience could help Every Cure ask better research questions and design studies focused on patient and physician priorities.
How will trials recruit patients?
Once Every Cure identifies a promising opportunity, it remains responsible for generating evidence on safety and effectiveness in the new disease, the company said. Every Cure will also address barriers to patient access. OpenEvidence said its role continues as programs move from research into the clinic.
For programs entering clinical trials, OpenEvidence said it will alert treating physicians when a patient may qualify. The announcement said the physician decides whether to pursue a referral. OpenEvidence said it will disseminate findings to physicians at the point of care as trial results emerge.
Isabel Ostrer, OpenEvidence’s director of primary care initiatives, said: “Physicians come to OpenEvidence for the best available evidence, but for thousands of diseases, that evidence doesn’t exist yet.” OpenEvidence said the recruitment support matters because eligible patients can be difficult to locate in rare diseases.
What experience does Every Cure bring?
Every Cure says its approach grew from co-founder and CEO David Fajgenbaum’s experience with idiopathic multicentric Castleman disease. After being told no options remained, Fajgenbaum identified an overactive immune pathway in his blood and tested sirolimus, an approved drug to prevent kidney-transplant rejection that targets the same pathway.
Every Cure says Fajgenbaum has been in remission for more than 11 years and has advanced 14 additional repurposed drugs. The announcement said the partnership joins that repurposing experience to OpenEvidence’s national clinical network.
OpenEvidence already works with the National Organization for Rare Disorders on more than 3,000 expert-reviewed rare-disease summaries, the company said. OpenEvidence also says its platform is used daily, on average, by a majority of U.S. physicians and is free for all verified U.S. clinicians.
OpenEvidence said that reach will support specialist matching, referrals and evidence distribution under the partnership. The announcement framed the central test as whether AI-assisted hypotheses, paired with specialist knowledge and physician reach, can become credible trial evidence and accessible treatments for patients who otherwise have few options.
Source: unite.ai
More from Amara Osei
Show full bio
Senior reporter covering companies, deals and strategy in entrepreneurship, startups and venture funding at Business Bearings.
2,136 articles